Pharmaust Limited ( (AU:NUZ) ) has provided an announcement.
Neurizon Therapeutics Limited announced positive results from a study conducted with Tessara Therapeutics, showcasing the safety and neuroprotective properties of their lead candidate, NUZ-001, in a 3D human brain model. The findings, which will be presented at a major international conference, suggest potential benefits for treating neurodegenerative diseases such as Alzheimer’s and Parkinson’s, with further studies underway to explore broader applications.
More about Pharmaust Limited
Neurizon Therapeutics Limited is a clinical-stage biotech company focused on developing treatments for neurodegenerative diseases. The company collaborates with Tessara Therapeutics, which specializes in 3D cell-based brain models, to advance its lead candidate, NUZ-001.
YTD Price Performance: -25.27%
Average Trading Volume: 5,836
Technical Sentiment Signal: Buy
Current Market Cap: €37.16M
For a thorough assessment of NUZ stock, go to TipRanks’ Stock Analysis page.